Price disclosure will only go part of the way to achieving lower prices for generic drugs
The Pharmaceutical Benefits Scheme (PBS) faces both challenges and opportunities. The challenges, which are well known, come when listing new pharmaceuticals. The Pharmaceutical Benefits Advisory Committee (PBAC) determines the cost-effectiveness of new drugs and recommends whether or not they should be listed on the PBS. Although there is no capped budget for the PBS, any drug the PBAC recommends for listing that is expected to cost more than $10 million per year must be approved by Cabinet. Budget pressures that last year caused the listing of several therapies for conditions including schizophrenia, chronic pain and severe asthma to be deferred1 are ongoing.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
I was funded by a National Health and Medical Research Council Career Development Award (ID 571122).
No relevant disclosures.